8,241 Shares in Natera, Inc. $NTRA Acquired by Keebeck Wealth Management

Key Points

• Keebeck Wealth Management acquired 8,241 Natera shares during the second quarter, worth approximately $2.24 million. Other institutions also initiated positions, with institutional investors collectively owning 99.90% of the stock.
• Natera reported stronger-than-expected quarterly results, posting an adjusted loss of $0.47 per share versus a $0.49 consensus loss and revenue of $752.75 million, up 37.7% year over year.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus and an average price target of $319.38, although insiders have sold 181,045 shares worth $41.3 million over the past 90 days.

Keebeck Wealth Management bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,241 shares of the medical research company's stock, valued at approximately $2,237,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NTRA. Keating Financial Advisory Services Inc. acquired a new position in shares of Natera during the 2nd quarter valued at $58,000. Encore Global Management LP acquired a new stake in shares of Natera in the second quarter valued at $1,629,000. Allworth Financial LP acquired a new stake in shares of Natera in the second quarter valued at $1,053,000. B. Metzler seel. Sohn & Co. AG bought a new position in Natera during the second quarter valued at about $840,000. Finally, Virtus Advisers LLC bought a new position in Natera during the second quarter valued at about $1,015,000. 99.90% of the stock is owned by institutional investors.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the transaction, the insider directly owned 129,019 shares in the company, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Herm Rosenman sold 16,530 shares of the business's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director directly owned 4,250 shares in the company, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 181,045 shares of company stock worth $41,330,968. 5.05% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on NTRA. Wall Street Zen cut shares of Natera from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. BTIG Research lifted their price objective on shares of Natera from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 target price for the company. Evercore restated an "outperform" rating and set a $300.00 target price on shares of Natera in a report on Monday, July 6th. Finally, Sanford C. Bernstein started coverage on shares of Natera in a research report on Friday, June 26th. They issued an "outperform" rating and a $310.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Natera has an average rating of "Moderate Buy" and an average target price of $319.38.

Natera Trading Up 2.2%

NTRA stock opened at $332.03 on Friday. Natera, Inc. has a one year low of $157.43 and a one year high of $333.56. The firm has a 50-day moving average of $274.24 and a two-hundred day moving average of $229.39. The firm has a market capitalization of $47.86 billion, a PE ratio of -244.14 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same period last year, the firm posted ($0.74) earnings per share. The firm's quarterly revenue was up 37.7% compared to the same quarter last year. On average, equities research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source